An FDA advisory committee voted 17 to 4, with one abstention, in favor of authorizing Pfizer and BioNTech’s COVID-19 vaccine candidate for individuals aged 16 years and older.
The FDA Vaccines and Related Biological Products Advisory Committee’s recommendation will play a role in the agency’s decision to grant an emergency use authorization (EUA) to the vaccine. Findings recently published in The New England Journal of Medicine confirmed that vaccine is 95% effective with two doses. The vaccine has already been approved for use in the United Kingdom and in Canada.
“The
Uncategorized